Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

Lingshu Wang(National Institutes of Health), Tongqing Zhou(National Institutes of Health), Yi Zhang(National Institutes of Health), Eun Sung Yang(National Institutes of Health), Chaim A. Schramm(National Institutes of Health), Wei Shi(National Institutes of Health), Amarendra Pegu(National Institutes of Health), Olamide K. Oloniniyi(National Institutes of Health), Amy R. Henry(National Institutes of Health), Samuel Darko(National Institutes of Health), Sandeep Narpala(National Institutes of Health), Christian Hatcher(National Institutes of Health), David R. Martinez(University of North Carolina at Chapel Hill), Yaroslav Tsybovsky(Leidos (United States)), Emily Phung(National Institutes of Health), Olubukola M. Abiona(National Institutes of Health), Avan Antia(National Institutes of Health), Evan M. Cale(National Institutes of Health), Lauren A. Chang(National Institutes of Health), Misook Choe(National Institutes of Health), Kizzmekia S. Corbett(National Institutes of Health), Rachel L. Davis(National Institutes of Health), Anthony DiPiazza(National Institutes of Health), Ingelise J. Gordon(National Institutes of Health), Sabrina Helmold Hait(National Institutes of Health), Tandile Hermanus(National Health Laboratory Service), Prudence Kgagudi(National Health Laboratory Service), Farida Laboune(National Institutes of Health), Kwanyee Leung(National Institutes of Health), Tracy Liu(National Institutes of Health), Rosemarie D. Mason(National Institutes of Health), Alexandra F. Nazzari(National Institutes of Health), Laura Novik(National Institutes of Health), Sarah O’Connell(National Institutes of Health), Sijy O’Dell(National Institutes of Health), Adam S. Olia(National Institutes of Health), Stephen D. Schmidt(National Institutes of Health), Tyler Stephens(Leidos (United States)), Christopher D. Stringham(National Institutes of Health), Chloe Adrienna Talana(National Institutes of Health), I‐Ting Teng(National Institutes of Health), Danielle A. Wagner(National Institutes of Health), Alicia T. Widge(National Institutes of Health), Baoshan Zhang(National Institutes of Health), Mario Roederer(National Institutes of Health), Julie E. Ledgerwood(National Institutes of Health), Tracy J. Ruckwardt(National Institutes of Health), Martin R. Gaudinski(National Institutes of Health), Penny L. Moore(National Health Laboratory Service), Nicole A. Doria‐Rose(National Institutes of Health), Ralph S. Baric(University of North Carolina at Chapel Hill), Barney S. Graham(National Institutes of Health), Adrian B. McDermott(National Institutes of Health), Daniel C. Douek(National Institutes of Health), Peter D. Kwong(National Institutes of Health), John R. Mascola(National Institutes of Health), Nancy J. Sullivan(National Institutes of Health), John Misasi(National Institutes of Health)
Science
July 1, 2021
10.1126/science.abh1766
Cited by 214Open Access
Full Text

Abstract

Defenses against SARS-CoV-2 variants Our key defense against the COVID-19 pandemic is neutralizing antibodies against the SARS-CoV-2 virus elicited by natural infection or vaccination. Recent emerging viral variants have raised concern because of their potential to escape antibody neutralization. Wang et al . identified four antibodies from early-outbreak convalescent donors that are potent against 23 variants, including variants of concern, and characterized their binding to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Yuan et al . examined the impact of emerging mutations in the receptor-binding domain of the spike protein on binding to the host receptor ACE2 and to a range of antibodies. These studies may be helpful for developing more broadly effective vaccines and therapeutic antibodies. —VV

Related Papers

No related papers found

Powered by citation graph analysis